|
|
| |
|
| |
Welcome to PharmaShots Weekly
| | | Jan 05 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
ABL Bio & Eli Lilly’s $2.6B Alliance Signals a New Era for Platform-Led Antibody Innovation
|
|
| | Harbour BioMed and Yantai Lannacheng Unite to Push Radiopharmaceuticals Into Precision Oncology’s Fast Lane
|
|
| | EirGenix Partners with Transcenta to Turn Continuous Bioprocessing Into a Competitive Advantage
|
|
| | Adlai Nortye and ASK Pharm Lock in China Rights to Fuel the Next Wave of Pan-RAS Oncology Drugs
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
| | Welcoming a New Year of Innovation
| | | in Biopharma and Healthcare
|
|
|
|
|
| |
A new year brings new possibilities. Thank you for being part of the PharmaShots community—here’s to breakthrough science, meaningful insights, and impactful stories driving the next wave of biopharma and healthcare innovation.
|
| |
|
| |
|
| |
|
| |
Biopharma 2026: From Recovery to Reckoning—Why Execution Is the New Alpha
|
| |
|
| |
Biopharma enters 2026 with cautious optimism—and far less patience for hype. After years of market volatility, capital discipline and policy uncertainty, the industry’s mandate is clear: convert science into sustainable growth. From boardrooms to the corridors of the J.P. Morgan Healthcare Conference, the prevailing mood is pragmatic and performance-driven. The message is consistent—prove the data, scale the capacity, and get paid for innovation in a tougher pricing and regulatory environment.
|
| |
From Bear Market Hangover to Renewal
|
| |
The sector continues its gradual recovery from the prolonged 2021–2024 biotech downturn. Specialist capital is re-engaging, but selectively—rewarding strong clinical differentiation, late-stage visibility, and clean launch execution. Roughly 70% of life sciences leaders expect revenue growth in 2026, yet lingering uncertainty remains, driven by patent cliffs, U.S. policy noise under President Trump, and geopolitical risk in China.
|
| |
What’s changed is mindset. The industry has shifted from survival mode to resilience: leaner pipelines, sharper portfolio prioritization, and a renewed focus on where each R&D or business development dollar truly moves the value needle.
|
| |
Obesity, Oncology, and the New “Must-Win” Arenas
|
| |
Obesity and cardiometabolic disease remain the sector’s strategic epicenter. GLP-1s and next-generation incretin therapies are not only reshaping earnings outlooks, but also forcing hard decisions around manufacturing scale, global supply, and long-term access economics.
|
| |
Oncology continues to anchor biopharma’s innovation engine. Multiple Phase III readouts and launches across solid tumors, bispecifics, and ADCs are expected in 2026, reinforcing cancer as the industry’s most reliable driver of returns. Alongside this, renewed momentum in CNS, mental health, and rare diseases, to be spotlighted heavily at upcoming JPM 2026 reflects where unmet need and regulatory incentives can still support premium pricing.
|
| |
AI, Reshoring, and a New Definition of Scale
|
| |
AI has crossed a threshold—from experimental promise to operational necessity. Executives increasingly view AI-enabled discovery, trial optimization, and commercial targeting as infrastructure, not innovation theater.
|
| |
At the same time, biomanufacturing is undergoing a geopolitical reset. More than $480 billion has already been committed to U.S. manufacturing and R&D projects as companies respond to reshoring pressure, tariff risks, and supply-chain fragility. Scale is no longer just about sales force size—it’s about resilient, globally compliant manufacturing capable of supporting chronic obesity therapies, cell and gene programs, and complex biologics at payer-acceptable costs.
|
| |
Deals, Capital, and the Late-Stage Land Grab
|
| |
Deal-making in 2026 is shaping up as a late-stage land grab. Large pharma is tilting decisively toward registrational or end-of-Phase II assets to shore up mid-2030s revenue gaps and avoid competitive bidding wars. Precision is the theme—structured deals and targeted acquisitions with clear reimbursement visibility are replacing broad platform bets that defined the last cycle.
|
| |
For biotech, the tone is cautiously bullish. Companies with clean balance sheets and compelling data are finding receptive investors once again, while weaker stories face consolidation, licensing pivots, or strategic retrenchment.
|
| |
A Year of Proving Power
|
| |
Ultimately, 2026 is a proving ground. Biopharma must demonstrate it can translate obesity and oncology pipelines, AI investments, and reshored manufacturing into durable growth under intensified payer and policy scrutiny. Launch excellence, market access sophistication, and real-world evidence generation now matter as much as scientific novelty.
|
| |
As the industry steps into the new year, expectations are grounded—but confidence is returning. Easy wins are gone. Discipline, execution, and operational rigor will determine whether 2026 becomes a true inflection point—or just another volatile chapter in global biopharma’s evolution.
|
| |
|
| |
| | $2.6B Bet on Next-Gen Biologics: ABL Bio and Eli Lilly Forge Strategic Platform Alliance
|
|
|
|
|
| |
ABL Bio and Eli Lilly Seal $2.6B Platform and Pipeline Partnership to Accelerate Innovation
|
| |
|
| |
Expanding Next-Generation Antibody and ADC Innovation
|
| |
ABL Bio has entered into a licensing, research, and collaboration agreement with Eli Lilly worth up to approximately $2.6 billion, under which ABL Bio will receive $55 million in total consideration, including $40 million in upfront payments and a $15 million equity investment.
|
| |
Why This Collaboration Matters
|
| |
| • | Significant capital infusion: ABL Bio secures $55 million in a blend of upfront cash and strategic equity investment from Eli Lilly, providing immediate non-dilutive and partnership-linked funding.
|
|
| • | Platform-driven collaboration: The partnership centers on ABL Bio’s proprietary Grabody® platform, which will be used to jointly develop multiple therapeutic candidates across diverse modalities.
|
|
| • | Pipeline and modality breadth: The deal spans bispecific immuno-oncology combinations, next-generation antibody–drug conjugates (ADCs), and other advanced biologic approaches.
|
|
| • | Focus on high-unmet-need diseases: Funding will support expansion of the Grabody® platform into obesity, muscle disorders, and other serious conditions with limited current treatment options.
|
|
| • | Long-term value potential: The overall deal structure, with ~$2.6 billion in total potential value, positions ABL Bio as a key innovation partner for Eli Lilly in complex antibody engineering and translational R&D.
|
|
| |
A Strategic Step Forward
|
| |
For ABL Bio, this collaboration represents a pivotal opportunity to scale its Grabody technology into multiple high-value indications while sharing development risk with a global pharma leader. For Eli Lilly, the alliance broadens access to cutting-edge bispecific and ADC capabilities that can feed its metabolic and oncology pipelines, reinforcing its commitment to novel biologics that address substantial unmet medical needs.
|
| |
Where Antibodies Meet Isotopes: Harbour BioMed and Lannacheng Advance Next-Gen RDCs
|
| |
Integrating Antibody Engineering and Radiopharma to Shape the Future of RDCs
|
| |
Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to co-develop next-generation radiopharmaceutical drug conjugates (RDCs).
|
| |
Why This Collaboration Matters
|
| |
| • | Complementary platform synergy: Harbour BioMed contributes its proprietary Harbour Mice® platform for fully human antibody discovery in conventional and heavy chain-only formats, optimizing targeting precision and safety.
|
|
| • | End-to-end radiopharma capabilities: Lannacheng provides integrated expertise in radiopharmaceutical R&D, isotope supply chains, and GMP-compliant manufacturing to streamline RDC progression from discovery to commercialization.
|
|
| • | Precision oncology acceleration: The partnership combines antibody engineering with radiopharma infrastructure to rapidly advance RDC candidates for high-precision cancer therapies.
|
|
| • | Risk-shared innovation model: Joint development reduces individual investment burdens while pooling specialized strengths for faster clinical translation.
|
|
| • | Broad therapeutic potential: Focus on next-generation RDCs positions both companies to capture growth in targeted radionuclide therapies beyond initial oncology applications.
|
|
| |
A Strategic Step Forward
For Harbour BioMed, the collaboration extends its Harbour Mice® antibodies into the high-growth radiopharmaceutical space, creating new revenue streams through differentiated RDC assets. For Lannacheng, partnering with Harbour BioMed enhances antibody sourcing for superior RDC constructs, strengthening its position as an end-to-end radiopharma innovator. Together, the alliance is poised to deliver precision radiotherapeutics that improve efficacy and safety profiles for patients with hard-to-treat cancers.
|
| |
EirGenix–Transcenta Alliance Signals a New Era in Continuous Bioprocessing
|
| |
Strengthening End-to-End CDMO Capabilities Through Continuous Bioprocessing
|
| |
EirGenix has entered into a strategic collaboration and non-exclusive licensing agreement with Transcenta to adopt its Highly Intensified Continuous Bioprocessing (HiCB) platform.
|
| |
Why This Collaboration Matters
|
| |
| • | Advanced technology access: EirGenix gains a non-exclusive license to Transcenta’s HiCB platform, including continuous perfusion, integrated hybrid purification, technical know-how, and regulatory support to enhance biologics production efficiency.
|
|
| • | Accelerated development timeline: The HiCB integration streamlines EirGenix’s biologics R&D and manufacturing workflows, enabling faster progression from lab to market.
|
|
| • | Expanded CDMO offerings: Licensing bolsters EirGenix’s service portfolio, positioning it to meet growing demand for high-throughput, cost-effective biologics contract development and manufacturing.
|
|
| • | Mutually beneficial economics: Transcenta receives upfront payments, milestones, and royalties tied to commercial deployment, validating the platform’s enterprise value.
|
|
| • | Strategic scalability: Continuous bioprocessing aligns with industry shifts toward intensified manufacturing, reducing costs and improving yields for complex biologics like monoclonal antibodies.
|
|
| |
A Strategic Step Forward
For EirGenix, the agreement fortifies its position as a next-generation CDMO by incorporating cutting-edge continuous processing, differentiating its services in a competitive biologics landscape. For Transcenta, it monetizes HiCB technology across multiple partners while retaining core expertise. Together, the collaboration advances more efficient, scalable biologics production to support global pipelines addressing unmet patient needs.
|
| |
Adlai Nortye–ASK Pharm Deal Strengthens China Rights for Pan-RAS Oncology Asset
|
| |
Expanding Pan-RAS Inhibitor Reach in High-Growth Oncology Markets
|
| |
Adlai Nortye has granted ASK Pharm exclusive rights to develop, manufacture, and commercialize AN9025 across mainland China, Hong Kong, and Macao, while retaining rights to the asset in all other global markets.
|
| |
Why This Licensing Deal Matters
|
| |
| • | Lucrative financial structure: Adlai Nortye receives more than $20 million in upfront and near-term milestones, plus up to ~$230 million total consideration with tiered royalties from high single-digit to mid-teens percentages on net sales in ASK Pharm’s territories.
|
|
| • | Strategic regional focus: ASK Pharm gains full control over AN9025 development, manufacturing, and commercialization in China, Hong Kong, and Macao—key markets for oncology innovation.
|
|
| • | High-potential asset: AN9025 is an oral pan-RAS(ON) inhibitor targeting multiple RAS mutations, showing durable preclinical antitumor activity in pancreatic, lung, and colorectal cancers.
|
|
| • | Accelerated clinical path: A Phase I study is planned for Q1 2026 initiation, positioning the asset for rapid proof-of-concept in difficult-to-treat RAS-driven tumors.
|
|
| • | Global retention flexibility: Adlai Nortye maintains rights outside Greater China, enabling parallel development and potential partnerships worldwide.
|
|
| |
A Strategic Step Forward
For Adlai Nortye, the deal de-risks AN9025 advancement in Asia’s largest pharma market while unlocking non-dilutive capital to fuel global programs. For ASK Pharm, securing this next-generation pan-RAS inhibitor bolsters its oncology portfolio with a differentiated oral therapy addressing critical unmet needs in RAS-mutated cancers. Together, the partnership accelerates access to transformative treatments for patients with aggressive, genetically defined solid tumors.
|
| |
|
| |
| | Scaling for Impact: Strategic Partnerships Power Global Manufacturing and Late-Stage Oncology Advancement
|
|
|
|
|
| |
|
| |
Intelligent Bio Solutions Partners with Syrma Johari to Scale Manufacturing Ahead of Global Expansion
|
| |
Enhancing Global Manufacturing Capacity and U.S. Market Entry
|
| |
Intelligent Bio Solutions (INBS) has entered into a strategic manufacturing partnership with Syrma Johari MedTech to scale production of its Intelligent Fingerprinting Drug Screening Reader.
|
| |
Why This Partnership Matters
|
| |
| • | Production scaling: The collaboration boosts INBS's manufacturing capacity to meet growing multi-region demand for its fingerprint-based drug screening technology.
|
|
| • | Supply chain resilience: Diversifying suppliers enhances operational flexibility and mitigates risks, supporting long-term margin expansion and efficiency.
|
|
| • | Strategic U.S. expansion: Partnership aligns with INBS's planned 2026 U.S. market entry, ensuring reliable supply for North American growth.
|
|
| • | New Asia hub: Syrma Johari will establish a medical-grade plastics facility in India starting January 2026, creating dedicated capacity for international medtech clients.
|
|
| • | Global strategy alignment: The deal positions INBS to serve workplace, justice, and healthcare sectors with rapid, non-invasive drug testing solutions.
|
|
| |
A Strategic Step Forward
For INBS, the partnership de-risks commercialization by securing scalable, cost-effective manufacturing ahead of U.S. entry, accelerating revenue growth from its innovative screening platform. For Syrma Johari, it expands its medtech footprint with high-precision diagnostics production. Together, the alliance strengthens access to advanced drug screening tools that deliver faster, more reliable results for safety-critical industries worldwide.
|
| |
BioAtla–GATC Health SPV Backs Pivotal Push for CAB-ROR2 ADC in Head & Neck Cancer
|
| |
Advancing CAB-ADC into Registrational Study with Retained Ownership
|
| |
BioAtla and GATC Health have announced a $40 million special purpose vehicle (SPV) transaction to advance ozuriftamab vedotin (Oz-V)—a conditionally active biologic (CAB)-ROR2 antibody–drug conjugate—into a registrational Phase III study for second-line and beyond oropharyngeal squamous cell carcinoma (OPSCC).
|
| |
Why This Funding Matters
|
| |
| • | Immediate capital access: BioAtla receives $5 million upfront to support operations and Phase III execution, with $35 million more closing in Q1 2026.
|
|
| • | Retained program control: BioAtla maintains 65% ownership of Oz-V across all solid tumor indications, preserving substantial long-term value.
|
|
| • | Accelerated regulatory path: BioAtla leads the Phase III through data readout targeting accelerated approval, with enrollment starting early 2026.
|
|
| • | FDA Fast Track validation: Oz-V holds Fast Track Designation for recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN).
|
|
| • | High-unmet-need focus: Targets second-line+ OPSCC, addressing poor prognoses in ROR2-expressing head and neck cancers.
|
|
| |
A Strategic Step Forward
For BioAtla, the SPV de-risks Oz-V advancement with non-dilutive funding while retaining majority control of this differentiated CAB-ADC asset. For GATC Health, it provides targeted exposure to a promising oncology program with registrational momentum. Together, the transaction positions Oz-V to deliver a novel, tumor-selective therapy that could transform outcomes for patients with advanced OPSCC and broader SCCHN indications.
|
| |
|
| |
| | Clinical Milestones That Matter: Phase III Data, Precision Imaging Advances, and Rare Disease Breakthroughs
|
|
|
|
|
| |
Phase III Setrusumab Topline Results
|
| |
|
| |
Osteogenesis Imperfecta (OI)
Mereo BioPharma Reports Phase III Setrusumab Topline Results
|
| |
Mereo BioPharma has reported topline results for setrusumab (UX143) from two global Phase III studies in patients with osteogenesis imperfecta (OI): the ORBIT trial versus placebo and the COSMIC trial versus intravenous bisphosphonates.
|
| |
Key Study Details
|
| |
| • | Trial populations: ORBIT enrolled 159 patients aged 5–25 years; COSMIC included 69 patients aged 2 to <7 years.
|
|
| • | Primary endpoints: Neither study met its primary endpoint of reducing annualized clinical fracture rate.
|
|
| • | Secondary endpoints: Both trials showed statistically significant improvements in bone mineral density (BMD) measures and consistent bone strength biomarkers.
|
|
| • | ORBIT findings: Meaningful BMD gains observed, but fracture reduction not achieved due to unexpectedly low placebo arm fracture rates.
|
|
| • | COSMIC findings: BMD improvements associated with numerically fewer fractures, though not statistically significant.
|
|
| |
Global Development Context
Additional analyses are ongoing to further characterize the clinical implications of setrusumab's BMD effects across both studies. Setrusumab, an anti-sclerostin antibody, continues to demonstrate consistent bone strengthening signals despite missing primary fracture endpoints in these pediatric and young adult OI populations.
|
| |
Why This Matters
The statistically significant BMD improvements across both Phase III trials validate setrusumab's mechanism in enhancing bone strength for OI patients, despite primary endpoint misses due to placebo fracture dynamics. These findings support Mereo BioPharma's ongoing data analyses and potential regulatory discussions, positioning setrusumab as a differentiated bone-building therapy for this rare, fracture-prone genetic disorder with limited treatment options.
|
| |
Gastrointestinal Cancers Imaging
SOFIE Biosciences Doses First Patient in Phase III FAPI-GO Trial
|
| |
SOFIE Biosciences has dosed the first patient with [¹⁸F]FAPI-74, a fluorine-18–labeled radiopharmaceutical, in its Phase III FAPI-GO trial evaluating the diagnostic performance of FAPI-targeted PET/CT imaging in gastrointestinal (GI) cancers.
|
| |
Key Study Details
|
| |
| • | Trial design: Multicenter Phase III study assessing [¹⁸F]FAPI-74 PET/CT clinical utility over 24 months in detecting metastatic disease.
|
|
| • | Patient population: 200 adults with gastroesophageal cancer across 18 clinical sites.
|
|
| • | FAPI-PRO expansion: Second Phase III study planned for December 2025 initiation in pancreatic ductal adenocarcinoma to evaluate metastatic disease detection.
|
|
| • | Technology focus: Fluorine-18 labeled FAPI-74 targets fibroblast activation protein for superior imaging in high-unmet-need GI malignancies.
|
|
| |
Global Development Context
The FAPI-GO trial initiation marks a critical step in validating FAPI-targeted PET/CT as a precision diagnostic platform across GI cancers, building on promising early data for improved metastatic detection sensitivity. The planned FAPI-PRO study extends this platform into pancreatic cancer, addressing one of oncology's most challenging diagnostic landscapes.
|
| |
Why This Matters
SOFIE's dual Phase III strategy positions [¹⁸F]FAPI-74 PET/CT to transform metastatic staging in GI cancers, where early detection dramatically impacts treatment selection and survival outcomes. By targeting fibroblast activation across gastroesophageal and pancreatic indications, this platform addresses critical gaps in current imaging technologies, potentially enabling more precise therapeutic decisions in these aggressive malignancies.
|
| |
Pathological Scarring & Fibrosis
|
| |
Mabwell Doses First Patient in Phase II 9MW3811 Trial
|
| |
Mabwell has dosed the first patient with 9MW3811 in its Phase II clinical trial (CTR20254857) in China, marking a key development milestone for the program in pathological scarring.
|
| |
Key Study Details
|
| |
| • | Trial progression: Follows successful Phase I completion in healthy volunteers across Australia and China, advancing to patient evaluation.
|
|
| • | Objectives: Phase II assesses safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with pathological scarring.
|
|
| • | Preclinical validation: Demonstrated robust antifibrotic activity in pulmonary fibrosis models and significant fibrosis/scar volume reduction in human keloid models.
|
|
| • | Expanded potential: Shows promise across hypertrophic scarring, abnormal endometrial bleeding, and broader fibrosis-related indications.
|
|
| |
Global Development Context
9MW3811 builds on strong Phase I safety data and compelling preclinical efficacy across multiple fibrotic conditions, positioning it as a potential first-in-class antifibrotic agent targeting unmet needs in scar management and tissue repair.
|
| |
Why This Matters
The Phase II initiation represents a critical inflection point for 9MW3811, transitioning from preclinical promise to clinical proof-of-concept in pathological scarring—a condition with limited effective therapies. Mabwell's advancement validates the candidate's potential to address fibrosis across dermatologic, pulmonary, and gynecologic applications, potentially establishing a new standard in antifibrotic treatment paradigms.
|
| |
Uveal Melanoma Liver Metastases
|
| |
Delcath Systems Publishes FOCUS Phase III Subgroup Analyses
|
| |
Delcath Systems has reported the publication of subgroup analyses from its Phase III FOCUS study in the Journal of Cancer Research and Clinical Oncology, further evaluating the efficacy and safety of the HEPZATO™ KIT for melphalan-based hepatic delivery in patients with unresectable metastatic uveal melanoma.
|
| |
Key Study Details
|
| |
| • | Patient cohort: Subgroup analyses of 91 patients from the FOCUS Phase III trial evaluating HEPZATO KIT (melphalan/hepatic delivery system).
|
|
| • | Low tumor burden benefit: Patients below median tumor burden showed superior ORR (51.1% vs. 22.2%) and PFS (11.3 vs. 5.8 months).
|
|
| • | Overall survival gains: Improved OS observed in low liver involvement (22.4 vs. 16.8 months), low tumor burden (26.7 vs. 15.4 months), and low/normal LDH (23.4 vs. 15.3 months).
|
|
| • | Response kinetics: Among 33 objective responders, 57.6% responded in Cycles 1–2; 33.3% responded in Cycles 4–6, supporting continued therapy.
|
|
| |
Global Development Context
These subgroup findings reinforce HEPZATO KIT's differentiated efficacy profile in liver-directed therapy for metastatic uveal melanoma, particularly among favorable baseline prognostic patients. The rapid response kinetics and OS benefits in key subgroups strengthen the clinical rationale for hepatic delivery in this orphan malignancy with limited systemic options.
|
| |
Why This Matters
The published FOCUS subgroup data highlight HEPZATO KIT's potential to deliver clinically meaningful outcomes in lower tumor burden uveal melanoma patients, addressing a critical prognostic segment. These findings support optimized patient selection strategies and underscore the value of continuing therapy through multiple cycles, positioning Delcath's platform as a precision liver metastasis treatment in this high-unmet-need setting.
|
| |
Hunter Syndrome (MPS II)
|
| |
NEJM Publishes DNL310 Phase I/II Results Showing Biomarker and Clinical Benefits
|
| |
The New England Journal of Medicine has published results from a Phase I/II study evaluating Denali Therapeutics' tividenofusp alfa (DNL310) for Hunter syndrome (mucopolysaccharidosis type II, MPS II), highlighting meaningful biomarker reductions and early clinical benefits.
|
| |
Key Study Details
|
| |
| • | Patient population: 47 participants aged 0.3–13 years (median age: 5), including ERT-naïve (n=15) and previously ERT-treated (n=32) patients.
|
|
| • | Biomarker reductions: At Week 49, CSF heparan sulfate reduced 91%, urine HS 88%, serum NfL 21% (deepening to 76% by Week 153).
|
|
| • | Clinical outcomes: Stabilization/improvement in adaptive behavior, cognition, hearing, plus liver volume normalization across systemic and neurologic domains.
|
|
| • | Regulatory status: BLA under FDA Priority Review (PDUFA April 5, 2026) with Breakthrough Therapy and Rare Pediatric Disease Designations.
|
|
| |
Global Development Context
Tividenofusp alfa demonstrates differentiated CNS penetration and disease modification potential versus standard ERT, addressing Hunter syndrome's progressive neurocognitive decline where current therapies show limited brain impact.
|
| |
Why This Matters
The NEJM publication validates DNL310's multimodal benefits across CSF biomarkers, neurodevelopment, and organ function in a genetically defined rare disease, positioning it as a potential transformative CNS-directed therapy. With Priority Review status, these data strengthen the path to approval, offering hope for improved long-term outcomes in young MPS II patients facing inevitable neurologic deterioration.
|
| |
|
| |
| | Regulatory Highlights: Key Global Approvals Across Multiple Therapeutic Areas
|
|
|
|
|
| |
Regulatory Momentum Builds: Global Approvals Signal Shifts Across Therapeutic Areas
|
| |
|
| |
Regulators in the U.S. and China delivered a surge of high-impact decisions this period, propelling a diverse slate of therapies through critical approval checkpoints. From first-in-class emergency treatments and accelerated oncology reviews to breakthrough designations and pivotal clinical filings, these milestones underscore how innovation is translating into regulatory traction—while also highlighting the rigor shaping the final steps to market.
|
| |
| • | CARsgen has submitted a dual IND application to China’s NMPA for CT0596, enabling Phase Ib/II trials in relapsed/refractory multiple myeloma and primary plasma cell leukemia.
|
|
| • | HUTCHMED secured NMPA acceptance of its NDA for fanregratinib in intrahepatic cholangiocarcinoma, with Priority Review granted—accelerating its regulatory pathway in China.
|
|
| • | ARS Pharmaceuticals announced NMPA approval of neffy 2 mg, an epinephrine nasal spray, for the treatment of Type I allergic reactions, marking a non-injectable emergency treatment milestone in China.
|
|
| • | Praxis Precision Medicines reported that the U.S. FDA granted Breakthrough Therapy Designation to ulixacaltamide for the treatment of essential tremor, underscoring its potential to address a significant unmet neurologic need.
|
|
| • | INOVIO disclosed that the U.S. FDA has accepted the BLA for INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), advancing the DNA-based immunotherapy toward potential approval.
|
|
| • | HUTCHMED announced NMPA acceptance of its NDA with Priority Review for savolitinib in gastric cancer patients with MET amplification, accelerating the regulatory pathway in a biomarker-defined oncology population.
|
|
| • | Vanda Pharmaceuticals reported U.S. FDA approval of Nereus (tradipitant) for the prevention of motion-induced vomiting, expanding therapeutic options in a common yet underserved condition.
|
|
| • | Ultragenyx completed its FDA rolling BLA submission for DTX401 for the treatment of glycogen storage disease type Ia (GSDIa), marking a key regulatory milestone for the gene therapy program.
|
|
| • | Cogent Biosciences announced the submission of an NDA to the U.S. FDA for bezuclastinib for non-advanced systemic mastocytosis, positioning the selective KIT inhibitor for regulatory review.
|
|
| • | FibroBiologics reported the submission of an IND application to the U.S. FDA for CYPS317 in patients with psoriasis, enabling the program’s transition into clinical development.
|
|
| • | Axsome Therapeutics disclosed that the U.S. FDA has accepted its sNDA with Priority Review for AXS-05 for the treatment of Alzheimer’s disease agitation, reflecting the urgency of addressing neuropsychiatric symptoms in dementia.
|
|
| • | Outlook Therapeutics provided an update on the FDA review of ONS-5010/Lytenava for wet age-related macular degeneration (AMD), as the biologic continues to progress through the regulatory process.
|
|
| • | Corcept Therapeutics announced receipt of a U.S. FDA Complete Response Letter (CRL) for relacorilant in hypercortisolism, noting the need for additional information before approval can be considered.
|
|
| |
|
| |
| | MedTech on the Move: Regulatory Progress Shaping Next-Gen Care Delivery
|
|
|
|
|
| |
MedTech Momentum: Regulatory Advances Powering the Next Generation of Care
|
| |
|
| |
From smarter wound care to AI-powered diagnostics and at-home cancer therapy delivery, the latest FDA actions signal accelerating momentum in medtech innovation. These milestones highlight how device developers are translating engineering and digital advances into regulatory progress—reshaping care pathways, improving patient experience, and expanding where and how treatment is delivered.
|
| |
| • | StimLabs announced U.S. FDA 510(k) clearance for TheraCor , its medical device for the management of acute and chronic wounds, strengthening its footprint in regenerative and wound care technologies.
|
|
| • | KORU Medical Systems disclosed that it has submitted a request for FDA clearance for the FreedomEDGE system, designed to enable delivery of PHESGO® in patients with HER2-positive breast cancer, supporting more flexible and patient-centric administration outside traditional infusion settings.
|
|
| • | CapsoVision reported the submission of a U.S. FDA 510(k) for an AI-assisted reading module integrated into CapsoCam Plus®, advancing the role of artificial intelligence in capsule endoscopy interpretation and clinical workflow efficiency.
|
|
| |
|
| |
| | Biosimilars in Motion: Expanding Access Across Global Markets
|
|
|
|
|
| |
Biosimilars Gain Momentum: Expanding Global Access and Market Reach
|
| |
|
| |
Mabwell has achieved a key market-entry milestone with marketing approval in Indonesia for its adalimumab injection, a Humira biosimilar, strengthening access to cost-effective biologic therapies in one of Southeast Asia’s fastest-growing healthcare markets.
|
| |
Samsung Bioepis has taken a decisive step in its commercial evolution by launching direct commercialization of Byooviz , its Lucentis biosimilar, across Europe—deepening its regional presence and reinforcing its ambition to shape the next phase of the global biosimilars market.
|
| |
|
| |
| | Advancing Animal Health: Elanco Expands Leadership in Canine Dermatology
|
|
|
|
|
| |
Elanco Secures USDA Approval for Befrena Launch in H1 2026
|
| |
|
| |
Elanco Animal Health has secured U.S. Department of Agriculture (USDA) approval for Befrena (tirnovetmab) for the treatment of canine allergic and atopic dermatitis, with commercial launch anticipated in H1 2026.
|
| |
Key Product Details
|
| |
| • | Targeted mechanism: Monoclonal antibody specifically targeting interleukin-31 (IL-31) to provide sustained pruritus relief in allergic/atopic dermatitis.
|
|
| • | Dosing convenience: Long-acting injections administered every 6–8 weeks, offering chronic management alternative to daily therapies.
|
|
| • | Related regulatory win: FDA approved Zenrelia (ilunocitinib) label changes in September, removing fatal vaccine-induced disease risk warning.
|
|
| |
Market Context
Befrena enters the growing veterinary biologics market for canine dermatology, where IL-31 inhibition has demonstrated transformative itch control. The extended 6–8 week dosing interval addresses key compliance challenges in chronic pet dermatoses.
|
| |
Why This Matters
USDA approval positions Elanco to capture significant share in the $2B+ U.S. canine dermatology market with a differentiated long-acting biologic. The dual regulatory successes—Befrena approval plus Zenrelia label optimization—strengthen Elanco's leadership in companion animal immunology, delivering veterinarians convenient, high-efficacy options for managing prevalent allergic skin conditions in dogs.
|
| |
|
| |
| | That’s a Wrap for This Week
We will see you next week
|
|
|
|
|
| |
From Breakthrough Science to Market Reality: This Week’s Signals Shaping Healthcare Innovation
|
| |
This week’s PharmaShots Weekly captures the momentum shaping biotech, medtech, and animal health—from billion-dollar platform alliances and next-gen oncology bets to pivotal clinical readouts, regulatory inflection points, and global market expansions. Across antibodies, radiopharma, gene therapy, diagnostics, biosimilars, and companion animal care, innovation is accelerating from discovery to delivery—reshaping pipelines, partnerships, and paths to approval worldwide.
|
| |
Stay curious. Stay informed. Stay ahead—with PharmaShots Weekly.
|
| |
We’ll be back next Monday at 8 AM EST with the insights that truly matter—pipeline inflection points, competitive dynamics, regulatory breakthroughs, and strategic moves—curated and distilled in minutes, not hours.
|
| |
If this edition challenged your thinking or sharpened your decisions, make it part of your routine. Subscribe to PharmaShots Weekly for a concise, credible intelligence brief built for industry leaders—delivered with precision, every week.
|
| |
Know someone in R&D, competitive intelligence, strategy, or business development who values insight over noise? Forward this issue. If a takeaway resonated, share it on LinkedIn and tag us—we’re happy to amplify thoughtful perspectives.
|
| |
The industry doesn’t slow down—and neither should your intelligence.
Let PharmaShots keep you one step ahead, every week.
|
| |
| | Questions?
Reach out to us [email protected] for any comments, questions, partnership and media inquiry.
|
|
|
|
|
| |
|
0 comments